Creasman W T, Omura G A, Brady M F, Yordan E, DiSaia P J, Beecham J
Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston.
Gynecol Oncol. 1990 Dec;39(3):239-43. doi: 10.1016/0090-8258(90)90244-f.
Four hundred and eleven evaluable patients with suboptimal (greater than 1 cm residual) stage III and IV and recurrent ovarian cancer after surgical exploration and tumor debulking were prospectively randomized to receive cyclophosphamide, doxorubicin, and cisplatin (CAP) with or without bacillus Calmette-Guerin (BCG). Therapy was planned for eight courses with the BCG to be given by the sacrification technique on Days 8 and 15 of each course. The addition of BCG did not improve response rate, progression-free interval (PFI), or survival. In a multivariate analysis prognostic factors significantly favorable for survival include nonmeasurable disease and young age. Those patients having tumor with a mucinous histology had poorer survival and PFI than patients with tumors composed of other cell types.
411例经手术探查和肿瘤减灭术后处于Ⅲ期和Ⅳ期且卵巢癌复发、预后欠佳（残留肿瘤大于1 cm）的可评估患者被前瞻性随机分组，分别接受环磷酰胺、阿霉素和顺铂（CAP）治疗，部分患者联合卡介苗（BCG）。计划进行8个疗程的治疗，卡介苗采用瘤内注射技术，于每个疗程的第8天和第15天给药。添加卡介苗并未提高缓解率、无进展生存期（PFI）或生存率。多因素分析显示，对生存显著有利的预后因素包括不可测量的疾病和年轻。与其他细胞类型肿瘤的患者相比，黏液组织学肿瘤患者的生存期和无进展生存期较差。
